This is the text extract for Funding Applications going to the February 2012 PTAC Meeting, browse documents here.
Funding Applications going to the February 2012 PTAC Meeting Details of Funding Applications received are published on PHARMAC’s website, in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and PTAC Subcommittees 2008. Chemical (Trade) names
Dutasteride (Avodart) Certolizumab (Cimzia) Vemurafenib (Zelboraf) Indacaterol (ONBREZ inhaler) Fingolimod (Gilenya) Eculizumab (Solaris) Eltrombopag (Revolade)
Indication
Benign Prostatic Hyperplasia Rheumatoid Arthritis Stage IIIC/IV Melanoma with BRAF V600 Mutation Chronic Obstructive Pulmonary Disease Multiple Sclerosis Paroxysmal Nocturnal Haemaglobinuria Idiopathic Thrombocytopenic Purpura (ITP)
Applicant
GlaxoSmithKline UCB Roche Novartis Novartis Alexion GlaxoSmithKline
Date Received
22/11/2011 22/11/2011 22/11/2011 22/11/2011 22/11/2011 22/11/2011 22/11/2011
Metadata
Title
Funding Applications going to the February 2012 PTAC Meeting
Abstract
Funding Applications going to the February 2012 PTAC Meeting Details of Funding Applications received are published on PHARMAC’s website, in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and PTAC Subcommittees 2008. Chemical (Trade)…
Page 1
Note
This text has been extracted from the source PDF document.
Also available as plain text.
Please contact webmaster to discuss alternative format options.
